About: Lessons learned from SARS-CoV and MERS-CoV: FDA-approved Abelson tyrosine-protein kinase 2 inhibitors may help us combat SARS-CoV-2

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Lessons learned from SARS-CoV and MERS-CoV: FDA-approved Abelson tyrosine-protein kinase 2 inhibitors may help us combat SARS-CoV-2 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Lessons learned from SARS-CoV and MERS-CoV: FDA-approved Abelson tyrosine-protein kinase 2 inhibitors may help us combat SARS-CoV-2
Creator	Izadi, Morteza Clementi, Emilio Nabavi, Seyed Bagheri, Mahdi Banach, Maciej Habtemariam, Solomon Berindan-Neagoe, Ioana Cismaru, Andrei Fazel Nabavi, Seyed Banach, Nabavi, Rasekhian, Mahsa Sadegh Bagheri, Mohammad Seyed, Mohammad
Source	Medline; PMC; WHO
abstract	covid:c2d5b6394bf9035b8502870d784e88719c1f6f27#abstract
has issue date	2020-04-14(xsd:dateTime)
bibo:doi	10.5114/aoms.2020.94504
bibo:pmid	32399097
has license	cc-by-nc-sa
sha1sum (hex)	c2d5b6394bf9035b8502870d784e88719c1f6f27
schema:url	https://doi.org/10.5114/aoms.2020.94504
resource representing a document's title	Lessons learned from SARS-CoV and MERS-CoV: FDA-approved Abelson tyrosine-protein kinase 2 inhibitors may help us combat SARS-CoV-2
has PubMed Central identifier	PMC7212214
has PubMed identifier	32399097
schema:publication	Arch Med Sci
resource representing a document's body	covid:c2d5b6394bf9035b8502870d784e88719c1f6f27#body_text
is schema:about of	named entity 'current' named entity 'therapy' named entity 'FDA-approved' named entity 'supportive treatment' named entity 'SARS-CoV-2' named entity 'infection' named entity 'cases' named entity 'SARS-CoV-2' named entity 'long' named entity 'reasonable' named entity 'SARS-CoV-2' named entity 'infection' named entity 'HIV protease inhibitors' named entity 'antiviral' named entity 'Wuhan' named entity 'FDA' named entity 'SARS-CoV-2' named entity 'province of China' named entity 'SARS-CoV-2' named entity 'SARS' named entity 'MERS' named entity 'infection' named entity 'SARS-CoV-2' named entity 'coronavirus' named entity 'FDA' named entity 'coronavirus' named entity 'lopinavir' named entity 'JAK/STAT' named entity 'approved drugs' named entity 'PI3K' named entity 'ritonavir' named entity 'MERS' named entity 'Ras' named entity 'infection' named entity 'infection' named entity 'Raf' named entity 'drug discovery' named entity 'Abl' named entity 'pathogenesis' named entity 'life cycle' named entity 'SARS-CoV-2' named entity 'combination therapy' named entity 'mortality rates' named entity 'internalisation' named entity 'antiviral drugs' named entity 'antiviral' named entity 'SARS-CoV-2' named entity 'kinase' named entity 'SARS' named entity 'tyrosine kinases' named entity 'HIV protease inhibitors' named entity 'kinase' named entity 'SARS-CoV-2' named entity 'anti-inflammatory drugs' named entity 'infection' named entity 'infectious bronchitis virus' named entity 'kinase inhibitors' named entity 'imatinib' named entity 'ritonavir' named entity 'saracatinib' named entity 'SARS-CoV-2' named entity 'SARS-CoV' named entity 'signalling pathways' named entity 'EGF receptor' named entity 'imatinib' named entity 'Saracatinib' named entity 'emerging infectious disease' named entity 'infection'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software